Original from: PathAI
PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation¡¯s top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI¡¯s digital pathology platform, AISight® Dx, across Moffitt¡¯s pathology programs to transform cancer detection and innovation.
AISight® Dx, is PathAI¡¯s cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine.
¡°We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,¡± said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. ¡°By deploying AISight® Dx and building this strategic partnership, we¡¯re equipping Moffitt¡¯s pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.¡±
¡°This collaboration aligns perfectly with Moffitt¡¯s mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,¡± said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. ¡°By deploying AISight® Dx into our pathology infrastructure, we¡¯re taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review.
¡°Adopting cutting-edge digital pathology technologies is key to driving Moffitt¡¯s vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,¡± said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. ¡°By partnering with PathAI, we¡¯re laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI¡¯s and Moffitt¡¯s legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.¡±
Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology.
